Table 4 Incidence of GVHD.

From: Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

GVHD, n (%)a

Midostaurin + SOC

(n = 30)

SOC

(n = 30)

Acute

15 (50)

16 (53)

 Grade I

7 (23)

4 (13)

 Grade II

8 (27)

10 (33)

 Grade III

0

2 (7)

 Grade IV

0

0

Chronic

9 (30)

10 (33)

 Mild

2 (7)

5 (17)

 Moderate

5 (17)

4 (13)

 Severe

2 (7)

1 (3)

  1. GVHD graft-vs-host disease, SOC standard of care.
  2. aPatients could be counted in multiple categories.
Back to article page